Photo / File
New Zealand shares rose as the export-orientated growth stocks A2 Milk and Xero extended recent gains, while insurer CBL Corp declined.
The S&P/NZX50 Index increased 23.17 points, or 0.3 per cent, to 8,060.98, another record close. Within the index, 21 stocks rose, 21 fell and eight were unchanged. Turnover was $194 million.
"It's more of the same today really, the glamour price-momentum stocks are carrying on their merry way," said Matt Goodson, managing director at Salt Funds Management. "I don't think the market is even remotely focused on when [a government is formed], I think it's more focused on what it is and what are the policies. The market hasn't paid a great deal of attention to date except via the currency which has been beneficial to a number of stocks who a weaker currency helps."
Stocks which have enjoyed recent gains extended that run with Synlait Milk up 3.8 per cent to $7.04, Xero gaining 3.1 per cent to $33.95, and A2 Milk Co rising 2 per cent to $7.75. This year, the stocks have respectively gained 118 per cent, 88 per cent and 257 per cent, ahead of the benchmark index's gain of 17 per cent. All three are export-focused businesses and have benefited from recent pressure on the kiwi dollar.
Fisher & Paykel Healthcare, another exporter, gained 1.3 per cent to $13.05 and Z Energy rose 1.3 per cent to $7.11.
CBL Corp was the worst performer, down 2.3 per cent to $2.98. It has made a technical adjustment to its minimum solvency capital, lifting it to $121m from $107m.
"It's come out that their minimum solvency capital is a little bit higher than previously stated, which would imply less headroom from their current capital position, though there still remains plenty of headroom," Goodson said.
New Zealand Refining Co fell 1.6 per cent to $2.48 and Metro Performance Glass declined 1 per cent to $1.02.
Outside the benchmark index, Pushpay Holdings rose 8 per cent to $2.96. The mobile payments app company said annualised committed monthly revenue (ACMR) has jumped 96.8 per cent and reiterated its target to break even on a monthly cash-flow basis before the end of 2018.
"It came out with some good numbers, they look like they're going to get to their revenue targets a bit quicker than initially planned," Goodson said. "We're in a market at the moment, across Asia and indeed globally, which is prepared to pay up aggressively for high-growth companies making their numbers."
Pacific Edge dropped 20 per cent to 36.5 cents. It wants to raise $21.3m at 32 cents apiece in a deeply discounted rights issue, which it says will fund the cancer diagnostics firm's goal of breaking even on a cash flow basis in the March 2019 year. The Dunedin-based company will sell 66.6 million shares in a one-for-six pro-rata rights offer, a 27 per cent discount to the theoretical ex-rights price of 44 cents, it said in a statement. The deal is fully underwritten by lead manager First NZ Capital Securities.
"The market is clearly hoping that they would be out with an announcement regarding Kaiser, a hugely influential client. That would still appear to be imminent, but not there yet. In the meantime, until they do build up their client base the business is still burning cash," Goodson said.